Safety and efficacy of GernaHair Premium supplement on Telogen Effluvium hair loss: A triple-blind, randomized, placebo-controlled clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 57 人开始时间: 待定最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•Patients with a history of hair loss who had clinical findings of female pattern hair loss (FPHL) Ludwig type II or I and parietal center telogen hair rate of more than 20%, as determined by TrichoScan
•Patients with diffuse hair loss without any evidence of underlying disease in medical history
•Patients with acquired or age-related damage to the hair structure, including thinning, brittle, or split end hair
•Patients with nail growth disorders such as soft or brittle nails with no evidence of underlying disease in the medical history

•Symptomatic diffuse alopecia (eg, due to iron deficiency or thyroid disorder)
•FPHL Ludwig type III
•Androgenic alopecia with or without virile symptoms as a result of polycystic ovaries, late-onset adrenogenital syndrome and ovarian, adrenal, or pituitary tumors
•Systemic autoimmune diseases
•Debilitating diseases (eg, AIDS or malignancy)
•Alopecia Areata
•Inflammatory ulcer or other ulcerative alopecia
•Other inflammatory conditions affecting the scalp (such as seborrheic dermatitis, psoriasis, or contact dermatitis)
•Receiving any treatment for hair loss or participating in another clinical trial for 3 months before entering the study
•Receiving medications that may cause hair loss (such as anticoagulants, lipid-lowering drugs, retinoids, antiepileptic drugs, antithyroid drugs, androgens, progesterones with androgenic or relative toxic effects, Angiotensin Converting Enzyme inhibitors(ACE) ) within 3 months before entering the study.
•Receiving drugs containing sulfonamides (interference with PABA)
•Initiation or termination of hormone replacement therapy or hormonal contraception within 6 months before entering the study
•Any type of hormone replacement therapy or oral contraceptive containing progesterone with an androgenic effect (such as Norethisterone, Norgestrel, levonorgestrel, Linsternol or Tibolone)
•Pregnancy or breastfeeding
•Known sensitivity to any of components

发起方